COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine

Fontana, Francesco; Alfano, Gaetano; Mori, Giacomo; Amurri, Alessio; Tei, Lorenzo; Ballestri, Marco; Leonelli, Marco; Facchini, Fiorenzo; Damiano, Francesca; Magistroni, Riccardo; Cappelli, Gianni

doi:10.1111/ajt.15935

Cited by 89 publications

(114 citation statements)

References 18 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…In a pilot study on 21 Chinese patients with severe COVID-19 pneumonia, tocilizumab was reported to improve lung function 11 and has also been demonstrated to be of benefit, in a renal transplant patient with COVID-19. 12 Ongoing randomized control trials will substantiate these observations. None the less, these preliminary observations are supportive of the view that IS may have a beneficial role in COVID-19 management, rather than per se increase the risk of COVID-19 pneumonia and death.…”

Section: Discussionmentioning

confidence: 95%

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

Verma

Khorsandi

Dolcet

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

Verma

Khorsandi

Dolcet

et al. 2020

Liver International

View full text Add to dashboard Cite

show abstract

“…56 Understanding the mechanisms underlying different prognosis in children is essential for designing targeted therapies for COVID-19. targeting the CRS and hyperinflammatory status of lung destruction via anti-IL-6R antibodies, [218][219][220][221][222][223][224][225][226][227][228][229][230][231][232][233][234][235][236][237] IL-1R antagonists, [238][239][240] JAK-STAT inhibitors, 241 or inhibition of entrance by anti CD147 antibodies 237 and destruction of the virus via protective antibody delivered with convalescent plasma 51,54,66,133,134,242 (Table 2). Eculizumab targets complement protein C5 preventing activation of complement terminal complex, which was used off label in patients with SARS-CoV-2 infection and severe pneumonia or ARDS and is now evaluated in an ongoing trail (SOLID-C19).…”

Section: Kids Versus Adults: Mechanisms Explaining the Clinical Difmentioning

confidence: 99%

Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)

Sokołowska

Łukasik

Agache

et al. 2020

Allergy

153

167

View full text Add to dashboard Cite

With the worldwide spread of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulting in declaration of a pandemic by the World Health Organization (WHO) on March 11, 2020, the SARS-CoV-2-induced coronavirus disease-19 (COVID-19) has become one of the main challenges of our times. The high infection rate and the severe disease course led to major safety and social restriction measures worldwide. There is an urgent need of unbiased expert knowledge guiding the development of efficient treatment and prevention strategies. This report summarizes current immunological data on mechanisms associated with the SARS-CoV-2 infection and COVID-19 development and progression to the most severe forms. We characterize the differences between adequate innate and adaptive immune response in mild disease and the deep immune dysfunction in the severe multiorgan disease. The similarities of the human immune response to SARS-CoV-2 and the SARS-CoV and MERS-CoV are underlined. We also summarize known and potential SARS-CoV-2 receptors on epithelial barriers, immune cells, endothelium and clinically involved organs such as lung, gut, kidney, cardiovascular, and neuronal system. Finally, we discuss the known and potential mechanisms underlying the involvement of comorbidities, gender, and age in development of COVID-19. Consequently, we highlight the knowledge gaps and urgent research requirements to provide a quick roadmap for ongoing and needed COVID-19 studies.

show abstract

“…Fontana et al described the use of TCZ in a COVID-19 kidney transplant recipient, who developed leukopenia with neutropenia as a possible side effect of TCZ; successfully treated with intravenous immunoglobulins 14. The most common side effects of TCZ are upper respiratory symptoms, headache and hypertension.…”

mentioning

confidence: 99%

First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19

Muhović

Bojovic

Bulatović

et al. 2020

Liver International

105

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in Wuhan, China in 2019. The disease it causes (coronavirus disease-19-COVID-19) was officially named on 11 February 2019 by the World Health Organization. At the beginning of May 2020, there are nearly 230 000 cases of COVID-19-related deaths and around 3 267 000 cases confirmed worldwide (WHO: COVID-19 Situation report-103.) The pathophysiology of COVID-19 includes SARS-CoV-2 binding to the alveolar epithelium, thus activating innate immune system and adaptive immune system and resulting in a pro-inflammatory cascade, including the release of

show abstract

COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine

Cited by 89 publications

References 18 publications

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience

Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)

First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19

Contact Info

Product

Resources

About